Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 229-237

  Farrell, John ^a   Naisbitt, Dean J ^a   Drummond, Nicola S ^a   Depta, Jan P H ^b   Vilar, F Javier ^c   Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; GLUTATHIONE; NITROSOSULFAMETHOXAZOLE; NITROSULFAMETHOXAZOLE; SEMIMERCAPTAL; SULFAMETHOXAZOLE; SULFAMETHOXAZOLE HYDROXYLAMINE; SULFINAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; CROSS REACTION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; CELLS, CULTURED; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MICE; RABBITS; RATS; SULFAMETHOXAZOLE; T-LYMPHOCYTES;

EID: 0038340979     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.050112     Document Type: Article

References (40)

1. Baron JM, Zwadlo-Klarwasser G, Jugert F, Hamann W, Rubben A, Mukhtar H, and Merk HF (1998) Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Pharmacol 56:1105-1110.
2. 4+ T-cells. Br J Pharmacol 132:623-630.
3. 4+ T cells. J Investig Dermatol 111:621-628.
4. Choquet-Kastylevsky G, Santolaria N, Tedone R, Aujoulat M, and Descotes J (2001) Induction of delayed-type hypersensitivity to sulfamethoxazole in mice: role of metabolites. Toxicol Lett 119:183-192.
5. Cribb AE, Miller M, Leeder JS, Hill J, and Spielberg SP (1991) Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 19:900-906.
6. Cribb AE, Miller M, Tesoro A, and Spielberg SP (1990) Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol Pharmacol 38:744-751.
7. Cribb AE, Spielberg SP, and Griffin GI (1995) N4-Hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 23:406-414.
8. Gill HJ, Hough SJ, Naisbitt DJ, Maggs JL, Kitteringham NR, Pirmohamed M, and Park BK (1997) The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J Pharmacol Exp Ther 282:795-801.
9. Gill HJ, Maggs JL, Madden S, Pirmohamed M, and Park BK (1996) The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Br J Clin Pharmacol 42:347-353.
10. Hashizume H, Takigawa M, and Tokura Y (2002) Characterization of drug-specific T cells in phenobarbital-induced eruption. J Immunol 168:5359-5368.
11. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, et al. (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121-1122.
12. Irvine DJ, Purbhoo MA, Krogsgaard M, and Davis M (2002) Direct observation of ligand recognition by T cells. Nature (Lond) 419:845-849.
13. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, et al. (2002) Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732.
14. Manchanda T, Hess D, Dale L, Ferguson SG, and Rieder MJ (2002) Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol 62:1011-1026.
15. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, and Pichler WJ (1995) Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 155:462-472.
16. Mitra K, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, and Slattery JT (1996) Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy. Clin Pharmacol Ther 59:332-340.
17. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JPH, Chadwick DW, Pichler WJ, Pirmohamed M, and Park BK (2003a) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype and cytokine profile of drug-specific T-cell clones. Mol Pharmacol 63:732-741.
18. Naisbitt DJ, Farrell J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, Pirmohamed M, and Park BK (2002) Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 62:628-1337.
19. Naisbitt DJ, Farrell J, Wong G, Depta JPH, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, et al. (2003b) Characterization of T-cells in Lamotrigine hypersensitivity. J Allergy Clin Immunol, in press.
20. Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, and Park BK (2001) Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 133:295-305.
21. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, and Park BK (1999) Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 126:1393-1407.
22. Naisbitt DJ, O'Neill PM, Pirmohamed M, and Park BK (1996) Synthesis and reactions of nitroso sulfamethoxazole with biological nucleophiles - implications for immune-mediated toxicity. Bioorg Med Chem Lett 6:1511-1516.
23. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, and Park BK (2000) Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses 16:1929-1938.
24. Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, and Roujeau JC (2002) Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Investig Dermatol 118:728-733.
25. O'Neil WM, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, and Svensson CK (2002) Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 42:613-619.
26. Ozkaya-Bayazit E and Akar U (2001) Fixed drug eruption induced by trimethoprimsulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. JAm Acad Dermatol 45:712-717.
27. Padovan E, Mauri-Hellweg D, Pichler WJ, and Weltzien HU (1996) T cell recognition of penicillin G: structural features determining antigenic specificity. Eur J Immunol 26:42-48.
28. Park BK, Pirmohamed M, and Kitteringham NR (1998) Role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. Chem Res Toxicol 9:969-988.
29. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, Kuechler P, and Naisbitt D (2002) Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 3:229-238.
30. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, and Park BK (2000) Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 10:705-713.
31. Pirmohamed M and Park BK (2001) HIV and drug allergy. Curr Opin Allergy Clin Immunol 1:311-316.
32. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, and Svensson CK (2000) A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Investig Dermatol 114:1164-1173.
33. Saeki M, Saito Y, Nagano M, Teshima R, Ozawa S, and Sawada J (2002) mRNA expression of multiple cytochrome P450 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol 127:333-336.
34. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, Park BK, and Pichler WJ (2000) Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 164:6647-6654.
35. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, and Pichler WJ (1997) Direct, MHC-dependent presentation of the drug sulfamethoxazole to human αβ T cell clones. J Clin Investig 100:136-141.
36. Summan M and Cribb AE (2002) Novel non-labile covalent binding of sulfamethoxazole reactive metabolites to cultured human lymphoid cells. Chem Biol Interact 142:155-173.
37. van der Ven AJ, Vree TB, van Ewijk-Beneken Kolmer EW, Koopmans PP, and van der Meer JW (1995) Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br J Clin Pharmacol 39:621-625.
38. von Greyerz S, Bultemann G, Schnyder K, Burkhart C, Lotti B, Hari Y, and Pichler WJ (2001) Degeneracy and additional alloreactivity of drug-specific human αβ(+) T cell clones. Int Immunol 13:877-885.
39. Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, and Wells PG (1997) Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS 11:1689-1697.
40. Yawalkar N, Hari Y, Frutig K, Egli F, Wendland T, Braathen LR, and Pichler WJ (2000) T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Investig Dermatol 115:647-652.